They are aimed at creating a biotechnology-clinical alliance for advanced translational therapies. It integrates elements of all other IMPACT R&D programs to converge with translational medicine, creating an interface between biology, engineering, and medicine.

It will add frontier capabilities and expertise in clinical trial design and redefinition of inclusion criteria, incorporating the electronic health record (EHR), big data analysis using AI and ML, and training of healthcare personnel in designing, monitoring, and evaluating clinical protocols. All this is closely linked with regulatory agencies to co-develop policies that promote the translation of research results to patients. Artificial Intelligence and Cross-Cutting Applications of Imaging and Biosensors – applications in cancer-associated, inflammatory and degenerative diseases.